Ohio State Navbar

Directory

Amy Johnson, PhD


Staff photo

410 W 12th Ave
OSU CCC Bldg. Room 455C
Columbus, OH 43210

Phone: (614) 292-8265

Email: johnson.2349@osu.edu

 

Current OSU Appointment

Associate Professor, Hematology

 

Clinical Interest

Chronic Lymphocytic Leukemia - CLL

Advising Narrative

I have been involved in the summer mentoring of students for our Hendrix College-The Ohio State University CLL Experimental Therapeutics Laboratory Summer Internship Program.

Noteworthy Graduate Narrative

I am a P status advisor for College of Pharmacy, Division of Pharmaceutics and the College of Medicine, Biomedical Sciences Graduate Program, (formerly IBGP). Sarah May Herman was an IBGP student who graduated with three first-author papers in Blood and went on to do a post-doctoral fellowship at the NIH. Dolly Rozewski was a Pharmaceutics PhD student and graduated with a first-author paper and is finishing her projects with Mitch Phelps in the College of Pharmacy as a post-doctoral fellow. Current PhD student, Ta-Ming Liu was awarded a Pelotonia fellowship in 2012.

Postdoctoral / Researcher Advising

I have mentored both PhD and MD post-doctoral researchers. Jennifer Woyach, MD was a hematology-oncology medical fellow that trained in my group studying BTK inhibitors in our mouse models. She is now a tenure-track faculty within the Division of Hematology, OSU and is the phase III clinical trial through the Alliance for Clinical Trials in Oncology cooperative group study chair. Her work has led to a Leukemia and Lymphoma Society Fellow award and a favorably scored K23 award. Kami Maddocks, MD was another hematology-oncology medical fellow that trained in my group who is now a tenure-track faculty in our Division and received a National Comprehensive Cancer Network (NCCN) award for a clinical trial with ibrutinib comparing outcomes in high and low-risk genetics CLL patients.

Academic Advising

2009 - present Emilia Mahoney The Ohio State University. Graduated 2009.
2011 - present Ta-Ming Liu The Ohio State University.
2011 - present Yuh-Ying Yeh The Ohio State University. Graduated 2010.
2011 - present Daphne Guinn The Ohio State University.
2011 - present Ta-Ming Liu The Ohio State University.
2011 - present Daphne Guinn The Ohio State University.
2013 - present Shuai Dong The Ohio State University.
2013 - present Shuai Dong The Ohio State University.
2009 - 2011 Sarah May-Herman The Ohio State University. Graduated 2010.
2009 - 2011 Sarah May-Herman The Ohio State University. Graduated 2010.
2010 - 2011 Kami Maddocks The Ohio State University. Graduated 2005.
2009 - 2012 Darlene Rozewski The Ohio State University. Graduated 2012.
2009 - 2012 Darlene Rozewski The Ohio State University. Graduated 2012.
2011 - 2012 Jennifer Woyach The Ohio State University. Graduated 2005.
 

Conferences

Johnson AJ, Hsu AL, Song X, Ching TT, Chen C-S. "Induction of Apoptosis by Cyclooxygenase-2 Inhibitors in Prostate Cancer Cells." In FASEB Journal. (March 2000). A1517-.

Johnson AJ, Song XQ, Lin HP, Chen C-S. "Is cyclooxygenase-2 a player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells?." In FASEB Journal. (March 2002). A178-A178.

Raval A, Rush LJ, Funchain P, Flak E, Davis M, Johnson AJ, Byrd JC, Plass C. "Aberrant DNA methylation in chronic lymphocytic leukemia: A role in pathogenesis?." In Blood. (November 2002). 379A-379A.

Mone AP, Lucas DM, Aron J, Cheney C, Johnson AJ Bains SK, Tso JY, Weiner G, Green J, Grever M, Byrd JC. "Hu1D10 induces parallel death and survival signals in chronic lymphocytic leukemia (CLL) cells: Justification for combination studies of Hu1D10 with PI3 kinase inhibitors.." In Blood. (November 2002). 386A-386A.

Mone AP, Cheney C, Huang P, Pelicano H, Green J, Tso JY, Johnson AJ, Byrd JC. "Hu1D10 activates both death and survival pathways in primary human chronic lymphocytic leukemia cells: Hu1D10 induced reactive oxygen species activate the AKT survival pathway.." In Blood. (November 2003). 438A-438A.

Johnson AJ, Eisenbeis CF, Cheney CM, Mone AP, Lucas DM, Byrd JC. "Rituximab and 17-AAG synergistically induce apoptosis in B-cell chronic lymphocytic leukemia (CLL).." In Blood. (November 2003). 437A-438A.

Johnson AJ, Eisenbeis C,; Cheney C, Mone AP, Lucas DM, Byrd JC. "Rituximab and 17-AAG synergistically induce apoptosis in B-cell chronic lymphocytic leukemia (CCL)." In Clinical Cancer Research. (December 2003). 6192S-6192S.

Johnson A, Smith L, Zhu JX, Heerema N, Guster S, Mone A, Grever M, Chen C-S, Byrd JCJ. "A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma via a caspase and Bcl-2 independent mechanism.." In Blood. (November 2004). 946A-946A.

Lin T, Blum K, Dalton J, Wu D, Fischer B, Moran M, Johnson AJ, Lucas DM, Heerema N, Lozanski G, Suarez J, Colevas A, Byrd JC, Grever MR. "Flavopiridol given as a 30-min intravenous (IV) bolus followed by 4-HR continuous IV infusion (CIVI) results in clinical activity and tumor lysis in refractory chronic lymphocytic leukemia (CLL)." In Annals of Oncology. (June 2005). 65-65.

Johnson AJ, Edwards R, Smith LL, Lucas DM, Croce CM, Muthusamy N, Chen C-S, Liu ZF, Chan K, Grever MR, Byrd JC. "The TCL-1 transgenic mouse is an effective tool for pre-clinical drug development in chronic lymphocytic leukemia." In Blood. (November 2005). 20A-20A.

Lucas DM, Hussain S-RA, Johnson AJ, Smith LL, Wagner AJ, Allison JM, Guster SE, Lin TS, Byrd JC, Julian MW, Crouser ED, Grever MR. "Flavopiridol decreases Mcl-1 and initiates early mitochondrial damage in chronic lymphocytic leukemia (CLL) cells.." In Blood. (November 2006). 595A-595A.

Johnson AJ, Wagner AJ, Smith LL, Lucas DM, De lay MD, Allison JM, Ivy SP, Lin TS, Byrd JC. "The geldanalmycin derivative DMAG demonstrates improved cytotoxicity and down-modulation of Hsp90 client proteins relative to 17-AAG in chronic lymphocytic leukemia (CLL) cells: Justification for clinical trials in CLL.." In Blood. (November 2006). 596A-596A.

Edwards RB, Lucas DM, Lozanski G, Johnson AJ, Su B-N, Lin TS, Byrd JC, Kinghorn AD, Grever MR. "Silvestrol, a rocaglate derivative from the Indonesian plant Aglaia foveolafa, has significant Bcl-2-and p53-independent anti-tumor activity against chronic lymphocytic leukemia cells.." In Blood. (November 2006). 734A-734A.

Zhang S, White VL, Johnson AJ, Chen C-S, Farag SS. "OSU03012, a novel celecoxib derivative, induces apoptogis in multiple myeloma cells independently of caspase activation.." In Blood. (November 2006). 358B-358B.

West DA, Lucas DM, Davis ME, De lay MD, Johnson AJ, Guster SE, Freitas MA, Parthun MR, Wang D, Kulp SK, Grever MR, Chen C-S, Byrd JC. "The novel histone deacetylase inhibitor OSU-HDAC42 has class I and II histone deacetylase (HDAC) inhibitory activity and represents a novel therapy for chronic lymphocytic leukemia.." In Blood. (November 2006). 794A-795A.

Blum W, Klisovic RB, Kefauver C, Johnson AJ, Phelps M, Dalton JT, Lucas DM, Colevas AD, Grever,M,R; Marcucci,G; Byrd,J,C. "Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, pharmacokinetics, and pharmacodynamics.." In Journal of Clinical Oncology. (June 2006). 353S-353S.

Blum W, Klisovic RB, Kefauver C, Johnson AJ, Phelps M, Dalton JT, Lucas DM, Huynh LN,, Liu S, Grever MR, Colevas AD, Marcucci G, Byrd JC. "Updated results of a phase I study of flavopiridol in acute leukemias using a novel, pharmacolkinetically derived schedule: Clinical activity including hyperacute tumor lysis syndrome (TLS), pharmacokinetics (PIC), and pharmacodynamics (PD).." In Blood. (November 2006). 224B-224B.

Lucas DM, Edwards RB, De lay MD, West DA, Lozanski G, Johnson AJ, Salim AA, Lin TS, Byrd JC, Kinghorn AD, Grever MR. "The plant-derived agent silvestrol has B-Cell selective activity in vitro in chronic lymphocytic leukemia patient cells and in vivo in the Tcl-1 mouse model of CLL." In Blood. (November 2007). 919A-919A.

De lay MD, Johnson AJ, Lucas DM, Durr DT, Sass EM, Goettl VM, Lehman A, Jaijoura D, Grever MR, Byrd JC. "Early fludarabine treatment of TCL-1 transgenic mice promotes drug resistance through a mechanism not involving p53 mutations: Implications for patients with chronic lymphocytic leukemia (CLL).." In Blood. (November 2007). 910A-911A.

Andritsos LA, Johnson AJ, Blurn W, Kefauver C, Awan F, Smith LL, Lapalombella R, Wang D-S, Knight RD, Chen C-S, Byrd JC. "Unacceptable toxicity of lenalidomide when administered to CLL patients at higher doses." In Blood. (November 2007). 255B-255B.

Lin TS, Fischer B, Blum KA, Andritsos LA, Jones JA, Moran ME, Broering S, Heerema NA, Lozanski G, Schaaf LJ, Mahoney LS, Johnson AJ, Smith LL, Wagner AJ, Raymond CA, Phelps M, Dalton JT, Grever MR, Byrd JC. "Preliminary results of a phase II study of flavopiridol (Alvocidib) in, relapsed chronic lymphocytic leukemia (CLL): Confirmation of clinical activity in high-risk patients and achievement of complete responses (CR).." In Blood. (November 2007). 913A-913A.

Heerema NA, Byrd JC, Andritsos LA, Lozanski G, Blum K, Fischer B, Jones JA, Moran ME, Groering S, Schaaf LJ, Mahoney LS, Johnson AJ, Smith LL, WagnerAJ, Raymond CA, Phelps MA, Dalton JT, Grever MR, Lin TS. "Clinical activity of flavopiridol in relapsed and refractory chronic lymphocytic leukemia (CLL) with high-risk cytogenetic abnormalities: Updated data on 89 patients (Pts).." In Blood. (November 2007). 914A-914A.

Blum W, Klisovic RB, Johnson AJ, Kefauver C, Phelps M, Lucas D, Huynh L, Liu S, Dalton JT, Grever MR, Marcucci G, Byrd JC. "Final results of a dose escalation study of flavopiridol in acute leukemias using a novel-treatment schedule." In Blood. (November 2007). 272A-272A.

Wagner AJ, Hertlein EK, Raymond CA, West DA, Flynn JM, Lin T, Johnson AJ, Byrd JC. "17-DMAG Targets the NF-kappa B Family of Proteins to Induce Apoptosis in CLL: Clinical Implications of Hsp90 Inhibition." In Blood. (November 2008). 147-147.

May SEM, Kashishian A, Lin TS, Jones JA, Flynn JM, Ulrich RG, Chen H, Yu AS, Puri KD, Lannutti BJ, Giese NA, Byrd JC, Johnson AJ. "CAL-101, a Selective Inhibitor of the p110 delta Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease." In Blood. (November 2008). 1085-1086.

Lannutti BJ, Meadows SA, Kashishian A, Steiner B, May SEM, Johnson AJ, Ulrich RG, Yu A, Gallatin MW, Byrd JC, Puri KD, Giese NA. "CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies." In Blood. (November 2008). 12-12.

Plass C, Chen S-S, Raval A, Johnson AJ, Byrd JC. "Epigenetic Contributions to Chronic Lymphocyte Leukemia." In Tumor Biology. (January 2008). 18-18.

Blum WG, Andritsos LA, Johnson AJ,; Klisovic RB, Kefauver C, Devine SM, Marcucci G, Byrd JC. "Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL): evidence of activity in acute myeloid leukemia (AML) and toxicity in CLL at starting dose." In Journal of Cliniclal Oncology. (May 2008). Abstract-.

Chen S-S, Johnson AJ, Claus R, Sablitzky F, Plass C, Byrd JC. "Loss of Id4 Accelerates CLL Progression in TCL1 Mice." In Blood. (November 2008). 1081-1081.

Lin TS, Heerema NA, Lozanski G, Fischer B, Blum KA, Andritsos LA, Jones JA, Flynn JM, Moran ME, Mitchell S, Johnson AJ, Phelps MA, Grever MR, Byrd JC. "Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities." In Blood. (November 2008). 23-24.

HeeremaNA, Lin TS, Fischer B, Lozanski G, Blum KA, Andritsos LA, Jones JA, Flynn JM, Moran ME, Mitchell SM, Schaaf LJ, Johnson AJ, Smith LL, Wagner AJ, Raymond CA, Phelps M, Dalton JT, Grever MR, Byrd JC. "Chronic lymphocytic leukemia (CLL) patients with high-risk cytogenetics respond to treatment with flavopiridol: Study of 120 patients (pts) with relapsed, genetically high risk CLL." In Cytogenetic and Genome Research. (January 2008). Abstract #46-.

Lannutti BJ, Meadows SA, Kashishian A, Steiner B, Pogosov G, Sala-Torra O, Johnson AJ, Byrd JC,; Radich J, Giese NA. "CAL-101, An Oral p110 delta Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment." In Blood. (November 2009). 120-121.

Hertlein EK, Lin TS, Amy WJ, William TH, Goettl VM, Zhang X, Jarjoura D, Raymond CA, West DA, Byrd JC, Johnson AJ. "The HSP90 Inhibitor 17-DMAG Targets NF-kappa B to Induce Apoptosis in CLL and Prolongs Survival in a CLL Mouse Model." In Blood. (November 2009). 305-305.

Flynn JM, Johnson AJ, Andritsos L, Blum KA, Jones JA, Wiley EA, Hu W, Hessler J, Smith LL, Lucas DM, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC. "The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia." In Blood. (November 2009). 365-365.

Maddocks K, Lapalombella R, Blum KA, Blum W, Fischer BB, Muthusamy N, Moran ME, Holtzapfel D, Byrd JC, Johnson AJ, Andritsos L. "Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.." In Blood. (November 2009). 1339-1339.

Stephens DM, Ruppert AS, Blum KA, Jones JA, Flynn JM, Johnson AJ, Ji Jia, Phelps M, Grever MR, Byrd JC. "Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients." In Blood. (November 2010). 592-593.

Jones JA, Andritsos L, Baiocchi RA, Benson DM, Blum KA, Christian B, Deam D, Flynn JM, Johnson AJ, Phelps MA, Porcu P, Byrd JC, Grever MR. "Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma." In Blood. (November 2010). 1169-1169.

Mahoney E, Johnson AJ, Wagner AJ, Hessler J, Gupta SV, Herman SEM, Andritsos L, Jones JA, Flynn JM, Lucas DM, Grever MR, Byrd JC. "Autophagy Is a Relevant Cellular Process In CLL and Contributes to Drug Resistance of Flavopiridol." In Blood. (November 2010). 305-305.

Woyach JA, Ruppert AS, Blum KA, Jones JA, Flynn JM, Johnson AJ, Grever MR, Byrd JC, Heerema NA. "Response, Progression-Free Survival, and Overall Survival of patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities." In Blood. (November 2010). 1019-1020.

Johnson AJ, Smith LL, Wagner AJ, Hessler J, Flynn JM, Jones JA, Zhang X, Lehman A, Jarjoura D, Grever MR, Bannerji R, Byrd JC. "Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines." In Blood. (November 2010). 428-428.

Hertlein EK, Yu L, Zhang J, Johnson AJ, Lucas DM, Marcucci G, Jarjoura D, Byrd JC. "Micro-RNA and Gene Expression In CLL: Network Analysis Elucidating the Complex Role of the NF-kappa B Signaling Pathway In Disease." In Blood. (November 2010). 1497-1498.

Herman SEM, Gordon AL, Mahoney E, Jaglowski SM, Blum KA, Buggy J, Hamdy A, Byrd JC, Johnson AJ. "The Kinase Inhibitor, PCI-32765, Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals." In Blood. (November 2010). 596-596.

Hofmeister CC, Bowers MA, Lee S, Phelps MA, Benson DM, Kraut EH, Hicks WJ, Deam D, Johnson AJ,; Farag S, Jones JA, Byrd JC. "Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia." In Blood. (November 2010). 804-804.

Herman SEM, Lapalombella R, Jones JA, Andritsos L, Gordon AL, Ramanunni A, Lannutti B, Muthusamy N, Byrd JC, Johnson AJ. "Lenalidomide-Dependent Activation of the Phosphatidylinositol 3-kinase-delta Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia.." In Blood. (November 2010). 760-761.

Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M, Johnson AJ, Grever MR, Byrd JC. "Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol." In Blood. (November 2010). 596-597.

Blum KA, Jones JA, Andritsos L, Flynn JM, Deam D, Heerema NA, Phelps M, Johnson AJ, Grever MR, Byrd JC. "Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)." In Blood. (November 2010). 1027-1027.

Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Hessler J, Wiley E, Poon J, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC. "Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration.." In Blood. (November 2010). 600-601.

Yang X, Hofmeister CC, Rozewski DM, Lee S, Chen P, Johnson AJ, Liu Z, Hade EM, Ji J, Schaaf LJ, Benson DM, Kraut EH, Hicks WJ, Chan KK, Chen C-S, Faraq SS, Grever MR, Byrd JC, Phelps MA. "The contribution of P-glycoprotein to clinical pharmacokinetic interactions between lenalidomide and temsirolimus." In Cancer Research. (March 2011). Abstrat #5473-.

Blum KA, Wei L, Jones JA, Andritsos LA, Flynn JM, Heerema NA, Yang X, Rozewski D, Phelps M, Johnson, AJ, Grever MR, Byrd, JC. "Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial.." In Blood. (December 2011). Abstract # 3910-.

Harshman SE, Johnson, AJ, Byrd, JC, Freitas, MA. "A Novel Approach for Charaterization Histone Isoform Distrubution Across Cellular Coparments." In Journal of the Amerian Society for Mass Spctrometry. (May 2011). Abstract #2090-.

Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Hessler J, Wiley E. Heerema NA, PooN, Small KA, Jou Y, Zhang D, Statkevich P, Grever MR, Bannerji R, Byrd JC. "Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL." In Journal of Clinical Oncology. (May 2011). Abstract #6623-.

Byrd JC, Blum KA, Burger JA, Coutre SE, Sharman JP, Furman RR, Flinn IW, Grant BW, Richards DA, Zhao W, Heerema NA, Johnson AJ, Izumi R. Hamdy A, O'Brien SM. "Activity and tolerability of he Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 in patients with chronis lymphocytic leukemia/small lymphocytic lymphoms (CLL/SLL): Interim results of a phase Ib/II stdy." In Journal of Clinical Oncology. (May 2011). Abstract # 6508-.

O'Brien S, Burger JA, Coutre SE, Sharman JP, Furman RR, Flinn IW, Grant B, Richards D, Heerema N; Johnson AJ, Izumi R, Hamdy A, Blum KA, Byrd JC. "The BTK Inhitibor PCI-32765 is highly active and tolerable in patients with poor-risk in CLL: Interim results from A Phase IB/II Study." In Annals of Oncology. (June 2011). 124-124.

Rao R, Maddocks K, Johnson AJ, Chauhan L, Kambhampati S, Ganguly S, Reyes R, Aljitawi OS, Schorno K, Ford K, Dickman E, Byrd JC, Bhalla KN. "Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells." In Blood. (November 2011). 423-423.

O'Brien S, Burger JA, Blum KA, Furman RR, Coutre SE, Sharman J, Flinn IW, Grant B, Heerema NA, Johnson AJ, Navarro T, Holmgren E, Hedrick E, Byrd JC. "The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study." In Blood. (November 2011). 449-450.

Lapalombella R, Ramanunni A, Yeh Y-Y, Wang L, Jha S, Staubli J, Herman SEM, Andritsos LA, Jones JA, Flynn JM, Mo X, Johnson, AJ, Thompson P, Algate PA, Stromatt S, Freitas MA, Muthusamy N, Byrd JC.. "Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals." In Blood. (December 2011). Abstract # 622-.

Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Sharman JP, Flinn IW, Grant BW, Heerema NA, Johnson AJ, Navarro T, James DF, Hedrick E, O'Brien SM. "The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study." In Journal of Clinical Oncology. (June 2012). Abstrct 6507-.

Dubovsky JA, Beckwith KA, Woyach JA, Jaglowski SM, Hessler J, Chang BY, Larkin K, Stefanovski MR, Frissora FW, Smith LL, Smucker KA, Flynn KM, Jones JA, Andritsos LA, Maddocks K, Lehman A, Furman RR, Sharman J, Mishra A, Caligiuri MA, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. "Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells." In Blood. (December 2012). 189-.

Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, Maddocks KJ, Blum KA, Grever MR, Geyer SM, Woyach JA, Johnson AJ, Heerema NA, Molnar E, Stefanos M, Devlin S, Navarro T, James DF, Lowe AM, Hedrick E, Byrd JC. "A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases." In Journal of Clinical Oncology. (June 2012). Abstract 6508-.

 

Degrees

1997 B.A., DePauw University

2002 Ph.D., University of Kentucky

 

Editorial Activities

2008 - present Blood
2008 - present Leukemia and Lymphoma
2009 American Society of Hematology Annual Meeting Abstract Reviewer, Molecular Pharmacology
2010 - present Blood Cells, Molecules and Diseases
2010 American Society of Hematology Annual Meeting, Molecular Pharmacology. Committee Chair
2011 - present Expert Opinion on Investigational Drugs
2011 American Society of Hematology Annual Meeting Abstract Reviewer, Molecular Pharmacology
2012 American Society of Hematology Annual Meeting Abstract Reviewer, CLL Biology
2013 - present Pharmaceutical Research
 

Honors

1995 Howard Hughes Foundation Summer Fellowship. Howard Hughes Medical Institute.
1996 ASPET Research Fellowship. American Society for Pharmacology and Experimental Therapeutics.
2000 ASPET Graduate Student Travel Award. American Society for Pharmacology and Experimental Therapeutics.
2002 ASPET Student Travel Award. American Society for Pharmacology and Experimental Therapeutics.
2003 - 2006 IDEC/Genetech/Ronald Levy Postdoctoral Fellowship. American Cancer Society.
 

Journal Articles

Johnson AJ, Song X, Hsu A,Chen C-S. "Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells." ADVANCES IN ENZYME REGULATION. Vol. 41, (January 2001.): 221-.

Ching TT, Hsu AL, Johnson AJ, Chen, C-S. "Phosphoinositide 3-kinase facilitates antigen-stimulated Ca2+ influx in RBL-2H3 mast cells via a phosphatidylinositol 3,4,5-trisphosphate-sensitive Ca2+ entry mechanism." JOURNAL OF BIOLOGICAL CHEMISTRY. Vol. 276, no. 18. (May 2001.): 14814-14820.

Johnson AJ, Hsu AL, Lin HP, Song X, Chen C-S. "The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks." THE BIOCHEMICAL JOURNAL. Vol. 366, no. Pt 3. (September 2002.): 831-837.

Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen C-S. "Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells." JOURAL OF THE NATIONAL CANCER INSTITUTE. Vol. 94, no. 8. (April 2002.): 585-591.

Johnson AJ, Mone AP, Abhyankar V, Byrd JC. "Advances in the therapy of chronic lymphocytic leukemia." CURRENT OPINION IN HEMATOLOGY. Vol. 10, no. 4. (July 2003.): 297-305.

Mone A, Huang P, Pelicano H, Cheney CM, Green JM, Tso JY, Johnson AJ, Jefferson S, Lin TS, Byrd JC. "Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells." BLOOD. Vol. 103, no. 5. (January 2004.): 1846-1854.

Rush LJ, Raval A, Funchain P, Johnson AJ, Smith L, Lucas DM, Bembea M, Liu TH, Heerema NA, Rassenti L, Liyanarachchi S, Davuluri R, Byrd JC, Plass C. "Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets." CANCER RESEARCH. Vol. 64, no. 7. (April 2004.): 2424-2433.

Johnson AJ, Smith LL, Zhu J, Heerema NA, Jefferson S, Mone A, Grever M, Chen C-S, Byrd JC. "A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism." BLOOD. Vol. 105, no. 6. (March 2005.): 2504-2509.

Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, Croce CM, Grever MR, Byrd JC. "Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia." BLOOD. Vol. 108, no. 4. (August 2006.): 1334-1338.

Johnson AJ, Wagner AJ, Cheney CM, Smith LL, Lucas DM, Guster SK, Grever MR, Lin TS, Byrd JC. "Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia." BRITISH JOURNAL OF HAEMATOLOGY. Vol. 139, no. 5. (December 2007.): 837-844.

Zhang S, Suvannasankha A, Crean CD, White VL, Johnson AJ, Chen C-S, Farag SS. "OSU-03012, a Novel Celecoxib Derivative, Is Cytotoxic to Myeloma Cells and Acts through Multiple Mechanisms." CLINICAL CANCER RESEARCH. Vol. 13, no. 16. (January 2007.): 4750-4758.

Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, Lucas DM, Byrd JC. "Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity." CLINICAL CANCER RESEARCH. Vol. 13, no. 7. (April 2007.): 2144-2150.

Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR. "Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia." BLOOD. Vol. 109, no. 2. (January 2007.): 399-404.

Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC, Lucas DM. "Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia." LEUKEMIA RESEARCH. Vol. 31, no. 12. (December 2007.): 1737-1740.

Grever MR, Lucas DM, Johnson AJ, Byrd JC. "Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia." BEST PRACTICE & RESEARCH. CLINICAL HEMATOLOGY. Vol. 20, no. 3. (September 2007.): 545-556.

Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG. "Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug." THE JOURNAL OF CLINICAL INVESTIGATION. Vol. 118, no. 7. (July 2008.): 2427-2437.

Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang DS, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen CS, Byrd JC. "Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia." JOURNAL OF CLINICAL ONCOLOGY. Vol. 26, no. 15. (May 2008.): 2519-2525.

Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ,; Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC. "Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells." BLOOD. Vol. 112, no. 13. (December 2008.): 5180-5189.

Andritsos LA, Lin TS, Blum W, Kefauver C, Johnson AJ, Byrd JC. "Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia - Reply." JOURNAL OF CLINICAL ONCOLOGY. Vol. 26, no. 29. (October 2008.): 4852-4853.

Liu Q, Farley KL, Johnson AJ, Muthusamy N,Hofmeister CC, Blum KA, Schaaf LJ, Grever MR,Byrd JC,Dalton JT, Phelps MA. "Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma." THERAPEUTIC DRUG MONITORING. Vol. 30, no. 5. (October 2008.): 620-627.

Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Dang VX, Viatchenko-Karpinski S, Ruppert AS, Byrd JC, Kuppusamy P, Crouser ED, Grever MR. "Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium." BLOOD. Vol. 111, no. 6. (March 2008.): 3190-3199.

Chen SS, Raval A, Johnson AJ, Hertlein E, Liu TH, Jin VX, Sherman MH, Liu SJ, Dawson DW, Williams KE, Lanasa M, Liyanarachchi S, Lin TS, Marcucci G, Pekarsky Y, Davuluri R, Croce CM, Guttridge DC, Teitell MA, Byrd JC, Plass C. "Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENES OF THE UNITED STATES OF AMERICA. Vol. 106, no. 32. (August 2009.): 13433-13438.

Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen C-S, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. "The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia." BRITISH JOURNAL OF HAEMATOLOGY. Vol. 144, no. 6. (March 2009.): 848-855.

Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Brooker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT. "Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia." BLOOD. Vol. 113, no. 12. (March 2009.): 2637-2645.

Johnson AJ. "Mighty mouse." BLOOD. Vol. 114, no. 1. (July 2009.): 3-.

Blum KA, Hamadani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS, Porcu P, Devine SM, Byrd JC. "Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma." LEUKEMIA & LYMPHOMA. Vol. 50, no. 3. (March 2009.): 349-356.

Chen SS, Sherman MH, Hertlein E, Johnson AJ, Teitell MA, Byrd JC, Plass C. "Epigenetic alterations in a murine model for chronic lymphocytic leukemia." CELL CYCLE. Vol. 8, no. 22. (November 2009.): 3663-3667.

Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, Goettl VM, Heerema NA, Lin TS, Lehman A, Zhang X, Jarjoura D, Newman DJ, Byrd JC, Kinghorn AD, Grever MR. "The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo." BLOOD. Vol. 113, no. 19. (May 2009.): 4656-4666.

Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM,; Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR, Byrd JC. "Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease." JOURNAL OF CLINICAL ONCOLOGY. Vol. 27, no. 35. (December 2009.): 6012-6018.

Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ. "Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals." BLOOD. Vol. 116, no. 12. (September 2010.): 2078-2088.

Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH 3rd; Goettl VM, Zhang X, Jarjoura D, Raymond CA, West DA, Croce CM, Byrd JC, Johnson AJ. "17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition." BLOOD. Vol. 116, no. 1. (July 2010.): 45-53.

Hamadani M, Liu K, Anthony BA, Gaughan A, Wang J-J, Shana'ah A, Byrd JC, Devine SM, Johnson AJ, Hadley GA. "CD103 Deficiency Separates Graft-Versus-Host Disease And Graft-Versus-Leukemia Effects Mediated By Donor CD8T Cells." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 16, no. 2. (February 2010.): S304-S304.

Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert AS, Porcu P, Kraut EH, Baiocchi RA, Moran ME, Johnson AJ, Schaaf LJ, Grever MR, Byrd JC. "Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders." JOURNAL OF CLINICAL ONCOLOGY. Vol. 28, no. 3. (January 2010.): 418-423.

Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen C-S, Ford R Jr, Rader C, Muthusamy N, Johnson AJ, Byrd JC. "Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway." BLOOD. Vol. 115, no. 13. (April 2010.): 2619-2629.

Lucas DM, Alinari L, West DA, Davis ME, Edwards RB,Johnson AJ, Blum KA, Hofmeister CC, Freitas MA, Parthun MR, Wang D, Lehman A, Zhang X Jarjoura D, Kulp SK, Croce CM, Grever MR, Chen C-S, Baiocchi RA, Byrd JC. "The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo." PLOS ONE. Vol. 5, no. 6. (January 2010.): e10941-.

Blum W, Phelps MA, Klisovic RB, Rozewski DM, Ni W, Albanese KA, Rovin B, Kefauver C, Devine SM, Lucas DM, Johnson AJ, Schaaf LJ, Byrd JCm Marcucci Grever MR. "Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias." HAEMATOLOGICA. Vol. 95, no. 7. (July 2010.): 1098-1105.

Ni W, Ji J, Dai Z, Papp A, Johnson AJ, Ahn S, Farley KL, Lin TS, Dalton JT, Li X, Jarjoura D, Byrd JC, Sadee W, Grever MR, Phelps MA. "Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition." PLOS ONE. Vol. 5, no. 11. (November 2010.): e13792-.

Awan FT, Johnson AJ, Lapalombella R, Hu W, Lucas M, Fischer B, Byrd JC. "Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.." LEUKEMIA & LYMPHOMA. Vol. 51, no. 1. (January 2010.): 27-38.

Hofmeister CC, Yang X, Pichiorri F, Chen P, Rozewski DM, Johnson AJ, Lee S, Liu Z, Garr CL, Hade EM, Ji J, Schaaf LJ, Benson DM Jr, Kraut EH, Hicks WJ, Chan KK, Chen CS, Farag SS, Grever MR, Byrd JC, Phelps MA. "Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein." JOURNAL OF CLINICAL ONCOLOGY. Vol. 29, no. 25. (September 2011.): 3427-3434.

Motiwala T, Zanesi N, Datta J, Roy S, Kutay H, Checovich AM, Kaou M, Zhong Y, Johnson AJ, Lucas DM, Heerema NA, Hagan J, Mo X, Jarjoura D, Byrd JC, Croce CM, Jacob ST. "AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia." BLOOD. Vol. 118, no. 23. (December 2011.): 6132-6140.

Herman SE, Lapalombella R, Gordon AL, Ramanunni A, Blum KA, Jones J, Zhang X, Lannutti BJ, Puri KD, Muthusamy N, Byrd JC, Johnson AJ. "The role of phosphatidylinositol 3-kinase-{delta} in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia." BLOOD. Vol. 117, no. 16. (April 2011.): 4323-4327.

Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M, Johnson AJ, Grever MR, Byrd JC. "Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol." LEUKEMIA. Vol. 25, no. 9. (September 2011.): 1444-1451.

Chen SS, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS, West DA, Williams KE, Johnson AJ, Sablitzky F, Plass C, Byrd JC. "Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL." BLOOD. Vol. 117, no. 3. (January 2011.): 862-871.

Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC. "Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765." BLOOD. Vol. 117, no. 23. (June 2011.): 6287-6296.

Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA. "CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability." BLOOD. Vol. 117, no. 2. (January 2011.): 591-594.

Rozewski DM, Herman SE, Towns WH 2nd, Mahoney E, Stefanovski MR, Shin JD, Yang X, Gao Y, Li X, Jarjoura D, Byrd JC, Johnson AJ, Phelps MA. "Pharmacokinetics and tissue disposition of lenalidomide in mice." AAPS journal. Vol. 14, no. 4. (December 2012.): 872-882.

Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas DM, Mo X, Daelemans D, Sandanayaka V, Shechter S, McCauley D, Shacham S, Kauffman M, Chook YM, Byrd JC. "Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia." Blood. Vol. 120, (November 2012.): 4621-4634.

Mahoney E, Lucas DM, Gupta SV, Wagner AJ, Herman SEM, Smith LL, Yeh Y-Y, Andritsos LA, Jones JA, Flynn JM, Blum KA, Zhang X, Lehman A, Kong H, Gurcan M, Grever MR, Johnson AJ, Byrd JC. "ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol." BLOOD. Vol. 120, no. 6. (August 2012.): 1262-1273.

Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, Byrd JC. "Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach." HAEMATOLOGICA. Vol. 97, no. 3. (March 2012.): 423-427.

Woyach JA, Johnson AJ, Byrd JC. "The B-cell receptor signaling pathway as a therapeutic target in CLL." BLOOD. Vol. 120, no. 6. (August 2012.): 1175-1184.

Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, Staubli J, Lucas DM, Mani R, Herman SE, Johnson AJ, Lozanski A, Andritsos L, Jones J, Flynn JM, Lannutti B, Thompson P, Algate P, Stromatt S, Jarjoura D, Mo X, Wang D, Chen CS, Lozanski G, Heerema NA, Tridandapani S, Freitas MA, Muthusamy N, Byrd JC. "Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals." CANCER CELL. Vol. 21, no. 5. (May 2012.): 694-708.

Johnson AJ, YehY-Y, Smith LL, Wagner AJ, HesslerJ, GuptaS, Flynn J, Jones J, Zhang X, Bannerji R, Grever MR, Byrd JC. "The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells." LEUKEMIA. Vol. 26, no. 12. (December 2012.): 2554-2557.

Johnson AJ and Herman SEM. "Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia." CLINICAL CANCER RESEARCH. Vol. 18, no. 15. (August 2012.): 4013-4018.

Troeger A, Johnson AJ, Wood J, Blum WG, Andritsos LA, Byrd JC, Williams DA. "RhoH is critical for cell-microenvironment interactions in Chronic Lymphocytic Leukemia in mice and humans." BLOOD. Vol. 119, (May 2012.): 4708-18.

Woyach JA, Lozanski G, Ruppert AS, Lozanski A, Blum KA, Jones JA, Flynn JM, Johnson AJ, Grever MR, Heerema NA, Byrd JC. "Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features." LEUKEMIA. Vol. 26, no. 6. (June 2012.): 1442-1444.

Mahoney E, Byrd JC, Johnson AJ. "Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol." AUTOPHAGY. Vol. 9, (March 2013.): 434-5.

Mahoney E, Maddocks K, Flynn J, Jones J, Cole SL, Zhang X, Byrd JC, Johnson AJ. "Identification Of Endoplasmic Reticulum Stress Inducing Agents By Antagonizing Autophagy: A New Potential Strategy For Identification Of Anti-Cancer Therapeutics In B-Cell Malignancies." LEUKEMIA LYMPHOMA. Vol. Epub ahead of print, (March 2013.): Epub ahead of print-.

Ji J, Mould DR, Blum KA, Ruppert AS, Poi M, Zhao Y, Johnson AJ, Byrd JC, Grever MR, Phelps MA. "A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol." CLINICAL CANCER RESEARCH. Vol. 19, (March 2013.): 1269-1280.

Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, Naresh K, Evens A, Gordon LI, Czader M, Gill JI, His ED, Liu Q, Fan A, Walsh K, Jima D, Smith LL, Johnson AJ, Byrd KC, Luftig MA, Ni T, Zhu J, Chadburn A, Levy S, Dunson D, Dave SS. "Genetic heterogeneity of diffuse large B-cell lymphoma." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENES OF THE UNITED STATES OF AMERICA. Vol. 110, (January 2013.): 1398-1403.

 

Inventions and Patents

Byrd JC, Grever MR, Johnson AJ, Lucas DM, Mahoney E. "Autophagosome-Lysosome Fusion Inhibition Enhances Flavopiridol Efficacy in Cancer." Filed November 2010.

Byrd JC, Johnson AJ, Mahoney E. "Identification of Denoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies." Filed October 2012.

Byrd JC, Johnson AJ, Lucas DM, Muthusamy N, Plass C. "TCL-1 Transgenic Mouse as a Model for Chronic Lymphocytic Leukemia." Filed April 2008.

 

Presentations

"The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia." Presented at ASH Annual Meeting, . (December 2005)

"Clinical rebirth of flavopiridol in chronic lymphocytic leukemia (CLL): Utilizing in vitro and in vivo pharmacodynamic measurements to improve efficacy and interrogate relevant mechanisms of action." Presented at AACR Annual meeting, . (April 2005)

"The cyclin dependent kinase inhibitor SCH 727965 demonstrates dramatic pre-clinical activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia." Presented at AACR Annual Meeting, Denver. (April 2009)

"Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines." Presented at ASH Annual Meeting, Orlando. (December 2010)

"The role of CDK and PI3 Kinase inhibitors in CLL." Presented at VIIIth International Workshop of the German CLL Study Group, Cologne, DE|DEU. (September 2010)

"CAL-101, a selective inhibitor of the p110 delta isoform of phosphatidylinositol 3-kinase, effectively induces apoptosis in chronic lymphocytic leukemia cells providing a novel therapeutic strategy." Presented at NCI Translational Science Meeting, Washington. (July 2011)

"Novel signaling inhibitors of CDK and PI3K." Presented at CLL Research Consortium Annual Meeting, . (April 2013)

"Novel therapies for CLL." Presented at International Association for Comparative Research on Leukemia and Related Diseases Symposium, . (September 2013)

"Mechanisms of resistance of kinase inhibitors and how to prevent this." Presented at International Workshop on CLL, . (September 2013)

 

Professional Activities

present Review of Grant Application. Italian Association for Cancer Research (AIRC).
2003 - present Leukemia and Lymphoma Society advocate.
2010 - present Pelotonia.
2004 - 2010 Newsletter Editor. Columbus Roadrunner Club. Columbus, OH.
2006 - 2010 American Cancer Society Volunteer Ambassador. American Cancer Society. Columbus, OH.
2011 Review of Grant Applications. French National Cancer Institute.
2012 Review of Grant Applications. Paracelsus Private Medical University of Salzburg.
2013 Review of Grant Applications. Cancer Research UK.
2013 Review of Grant Applications. Austrian Science Fund.
 

Unpublished Works

Hertlein E, Beckwith K, Lozanski G, Chen TL, Towns WT, Johnson AJ, Lehman A, Ruppert AS, Bolon B, Lozanski A, Rassenti L, Zhao W, Jarvinen T, Senter L, Symer DE, Chapelle Adl, Heerema N, Byrd JC. Characterization of a New Chronic Lymphocytic Leukemia Cell Line As a Useful Tool For Mechanistic In Vitro and In Vivo Studies Relevant to this Disease. April 2013.

Dubovsky JA, Beckwith KA, Gayathri N, Woyach JA, Jaglowski S, Hessler J, Liu T-M, Chang BY, Larkin KM, Stefanovski MR, Fissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritso LA, Maddocks K, Lehman AM, Fuman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Ibrutinib is an irreversible molecular inhibitor of Interleukin-2 Inducible Kinase: Expanding therapeutic potential and modulating a Th1 selective pressure in CD4 T-cells. April 2013.

Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Davis ME, Mao Y, Laurenti L, Chang BY, Buggy JJ, Efremov DG, Byrd JC, and Johnson AJ. Bruton Tyrosine Kinase (BTK) Function is Important to the Development and Expansion of Chronic Lymphocytic Leukemia (CLL). April 2013.

Lanasa MC, Andritsos LA, Brown JR, Gabrilove J, Federico Caligaris-Cappio F, Ghia P, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Bühler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR. Final Results of EFC6663: A Multicenter, International, Phase 2 Study of Alvocidib for Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. May 2013.